Key result
YAP2 promotes cardiomyocyte hypertrophy and the development of hypertrophic cardiomyopathy by upregulating Akt1 activity.
Why the study?
The relationship between YAP2 and hypertrophic cardiomyopathy and the signaling pathways involved in HCM pathogenesis remained to be explored.
Answers are grounded in this paper and cite their sources.
YAP2 acts as a critical mediator of cardiomyocyte hypertrophy in hypertrophic cardiomyopathy via the Hippo/AKT1 signaling pathway, identifying it as a potential novel therapeutic target.
Hypertrophic cardiomyopathy (HCM) is a heterogeneous myocardial disease characterized by myocardial hypertrophy, myocardial mechanical and electrical activity obstacles. This study aimed to explore the relationship between YAP2 (Yes-associated protein 2) and HCM and clarify a signaling path about the pathogenesis of HCM. Our study confirms that YAP2 can promote myocardial cell hypertrophy at the molecular level (myocardial lineage cell H9C2), organ level (clinical specimens of human HCM), and an animal model (a mouse model of HCM with cardiac-specific transgenic and knockout YAP2). The detailed molecular mechanisms linking YAP2 to cardiomyocyte hypertrophy and HCM were investigated. This study proved that YAP2, as the final reaction factor in Hippo pathways, influences Akt1 activity to affect the downstream genes, which participate in the formation of HCM by promoting myocardial cell proliferation and cardiac hypertrophy.
No takes yet. Share an insight, caveat, or question.
Song et al. (2021) studied Hypertrophic cardiomyopathy (n=18). YAP2 overexpression or knockdown vs. Wild-type, sham, or GFP control was evaluated on Cardiomyocyte hypertrophy and Akt1 activity (p=<0.05). YAP2 promotes cardiomyocyte hypertrophy and the development of hypertrophic cardiomyopathy by upregulating Akt1 activity.
Synapse has enriched 10 related papers. Consider them for comparative context: